Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Maravai Lifesciences Holdings (MRVI) Debt to Equity: 2020-2025

Historic Debt to Equity for Maravai Lifesciences Holdings (MRVI) over the last 5 years, with Sep 2025 value amounting to $0.68.

  • Maravai Lifesciences Holdings' Debt to Equity fell 20.37% to $0.68 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.68, marking a year-over-year decrease of 20.37%. This contributed to the annual value of $0.51 for FY2024, which is 22.74% down from last year.
  • Latest data reveals that Maravai Lifesciences Holdings reported Debt to Equity of $0.68 as of Q3 2025, which was up 7.98% from $0.63 recorded in Q2 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' Debt to Equity peaked at $2.54 during Q1 2021, and registered a low of $0.51 during Q4 2024.
  • Over the past 3 years, Maravai Lifesciences Holdings' median Debt to Equity value was $0.66 (recorded in 2023), while the average stood at $0.66.
  • Per our database at Business Quant, Maravai Lifesciences Holdings' Debt to Equity crashed by 60.28% in 2021 and then surged by 44.73% in 2024.
  • Quarterly analysis of 5 years shows Maravai Lifesciences Holdings' Debt to Equity stood at $1.37 in 2021, then tumbled by 57.54% to $0.58 in 2022, then grew by 13.89% to $0.66 in 2023, then declined by 22.74% to $0.51 in 2024, then decreased by 20.37% to $0.68 in 2025.
  • Its last three reported values are $0.68 in Q3 2025, $0.63 for Q2 2025, and $0.56 during Q1 2025.